KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”
January 06 2022 - 7:30AM
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical
company focused on the discovery and development of proprietary
prodrugs, announced today the company is participating in BIO
Partnering @ JPM, which is being held virtually alongside the J.P.
Morgan 40th Annual Healthcare Conference 2022.
Details of the events are as follows:
Event: |
|
BIO Partnering @ JPM |
Date: |
|
January 10-14, 2022 |
Registration: |
|
https://www.bio.org/events/bio-partnering-jpm/registration |
During BIO Partnering @ JPM, members of the
KemPharm management team will participate in virtual one-on-one
meetings with registered investors and pharmaceutical companies to
discuss KemPharm’s recent corporate achievements and anticipated
milestones, its serdexmethylphenidate development pipeline, and
commercial products, including AZSTARYS®.
About
AZSTARYS®:
AZSTARYS is an FDA-approved, once-daily product
for the treatment of attention deficit hyperactivity disorder
(ADHD) in patients age six years or older. AZSTARYS consists of
SDX, KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated
with immediate release d-MPH. Corium, Inc., a portfolio company of
Gurnet Point Capital, is leading all commercialization efforts for
AZSTARYS in the U.S.
The complete approved prescribing information
for AZSTARYS may be downloaded in PDF format
here: https://kempharm.com/wp-content/uploads/2021/03/AZSTARYS-Master-Label-Final_20210302.pdf
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LAT®
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LAT® technology to generate improved prodrug versions
of FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s prodrug product candidate pipeline is
focused on the high need areas of attention deficit hyperactivity
disorder, or ADHD, stimulant use disorder (SUD) and CNS rare
diseases, including idiopathic hypersomnia (IH). In addition, the
U.S. Food and Drug Administration (FDA) has approved AZSTARYS®, a
new once-daily treatment for ADHD in patents age six years and
older containing KemPharm’s prodrug, serdexmethylphenidate (SDX),
and APADAZ®, an immediate-release combination product containing
benzhydrocodone, KemPharm’s prodrug of hydrocodone, and
acetaminophen. For more information on KemPharm and its pipeline of
prodrug product candidates visit www.kempharm.com or connect with
us on Twitter, LinkedIn, Facebook and YouTube.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc.Jason
Rando/Maureen McEnroe, CFA(212) 375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2023 to Apr 2024